Loading
Gold and Silver Nanoparticles Synthesis and Applications · Journal article
Acs Applied Bio Materials · August 18, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a preclinical proof-of-concept report of a novel far-red emitting platinum nanocluster probe for tumor-targeted fluorescence imaging in living organisms. The nanoprobes accumulated in MDA-MB-231 breast tumor tissue and enabled tracking of PAR1 expression, but the work is early-stage and lacks comparison to standard imaging agents or quantitative efficacy data.
Preclinical in vivo imaging study, single-arm. MDA-MB-231 metastatic breast cancer tumor-bearing model. Intervention: Far-red emitting Pt nanocluster-based bio-nanoprobes (Pt NC, carboxylic acid-protected, conjugated with antibodies targeting PAR1).
Pt nanoprobes exhibit far-red emission (Em/Ex = 680/580 nm) with ultrasmall diameter of 0.8 ± 0.2 nm Pt nanoprobes demonstrated high photostability and long colloidal stability in biological conditions over weeks Pt nanoprobes successfully accumulated in MDA-MB-231 breast tumor tissues and enabled in vivo tracking of PAR1 marker protein
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This nanomaterial represents early development toward non-invasive molecular imaging of tumor biomarkers. Clinical translation would require comparison to existing imaging agents (e.g., fluorescence endoscopy, PET tracers), safety data, and human studies before changing practice.
Early-stage proof-of-concept study demonstrating a novel nanomaterial's feasibility for tumor imaging in vivo, without comparison to a standard imaging agent or clinical validation.
As stated by the source record.
Quoted from the source exactly as published.
This nanomaterial represents early development toward non-invasive molecular imaging of tumor biomarkers. Clinical translation would require comparison to existing imaging agents (e.g., fluorescence endoscopy, PET tracers), safety data, and human studies before changing practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Abstract Biomedical imaging has become an indispensable tool in the fields of cancer diagnosis and therapy. Fluorescent noble metal nanoclusters (NCs) are promising nanomaterials for biomedical applications. However, among the noble metal NCs, there is very little research on the biomedical application of platinum (Pt) NCs even though Pt NCs exhibit excellent optical properties. Our far-red emitting (Em/Ex = 680/580 nm) Pt NC-based bio-nanoprobes (Pt nanoprobes) possess ultrasmall size (0.8 ± 0.2 nm in diameter), high photostability, and biocompatibility, and these Pt nanoprobes are promising probes for in vivo imaging. Herein, we report the biomedical application of Pt nanoprobes and demonstrate that the far-red emitting Pt nanoprobes act as an in vivo contrast agent for precise fluorescence imaging of expressed marker protein (protease-activated receptor 1 (PAR1)) at metastatic breast cancer. The carboxylic acid-protected Pt NCs exhibit strong photostability and long colloidal stability over weeks in biological conditions, allowing us to prepare Pt nanoprobes by conjugating with antibodies of targeted biomolecules. Moreover, Pt nanoprobes have successfully been accumulated in MDA-MB-231 breast tumor tissues and further enable highly efficient in vivo tracking of the marker protein (PAR1). Therefore, the developed far-red emitting Pt nanoprobes can be utilized to monitor the physiological behavior of targeted biomolecules in living organisms.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.